And what will distinguish the neutraceutical from the prescription version being contemplated from a science perspective?
That's what I would like to know. Also, are they planning on building on the chemistry to make a more powerful anti-inflammatory, or are they going to ride 'anatabine' one indication at a time in an attempt to fully leverage their asset?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.